Clinical Trial

Prevention of Oral Mucositis in Head and Neck Cancer.

Study acronym: OMHNC-1
Recruiting
View on ClinicalTrials.gov →
Summary
Oral Mucositis (OM) consists in the painful inflammation and ulceration of the mucous membranes lining the digestive tract, lasting between 7 and 98 days; and starts as an acute inflammation of oral mucosa, tongue, and pharynx after RT exposure. Gel X spray is a product based on zinc gluconate. It could be helpful to achieve the prevention of Oral Mucositis and, in case of OM manifestation, the reduction of oral pain symptoms and to accelerate the healing process of oral mucositis ulcerations. The aim of this study is to demonstrate the efficacy of the treatment with Gel X to reduce the incidence of oral mucositis, in comparison with Sodium Bicarbonate.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-08.
Trial Details
NCT Number NCT05853692
Lead Sponsor Catholic University of the Sacred Heart
Conditions Oral Mucositis
Enrollment 130 participants
Start Date 2022-10-10
Primary Completion 2027-10-10 (estimated)
Study Completion 2028-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-19